Roth Capital reiterated their buy rating on shares of Arch Therapeutics (OTCMKTS:ARTH) in a research report sent to investors on Tuesday morning.
ARTH has been the subject of several other reports. Zacks Investment Research raised Arch Therapeutics from a sell rating to a hold rating in a report on Tuesday, January 2nd. HC Wainwright set a $3.00 target price on Arch Therapeutics and gave the company a buy rating in a report on Tuesday, December 19th. Finally, Ifs Securities downgraded Arch Therapeutics from a strong-buy rating to an outperform rating in a report on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Arch Therapeutics presently has an average rating of Hold and an average target price of $2.17.
Shares of ARTH stock opened at $0.30 on Tuesday. Arch Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $0.89.
TRADEMARK VIOLATION WARNING: “Arch Therapeutics (ARTH) Receives “Buy” Rating from Roth Capital” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/19/arch-therapeutics-arth-receives-buy-rating-from-roth-capital.html.
About Arch Therapeutics
Arch Therapeutics, Inc, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.